Panelists discuss how the current treatment landscape for chronic graft-versus-host disease includes a range of immunosuppressive approaches, from traditional corticosteroids and calcineurin ...

“We [as oncology nurses] end up establishing good rapports with our patients, and we’re basically the frontlines to nutritional deficiencies,” DiRubbo said. “So assessing nutritional needs from the ...

Panelists discuss how physician assistants educate and empower chronic graft-versus-host disease patients and their caregivers to recognize, report, and manage symptoms effectively, detailing ...

Oncology nurses and APPs play a role in supporting caregivers while the patient they care for receives a diagnosis and cancer ...

Belantamab plus VRd led to promising outcomes in newly diagnosed transplant-eligible myeloma, study results showed.

Oncology nurses should inform patients about adverse events and the signs of interstitial lung disease before treating their breast cancer with T-DXd.

Olaparib after surgery resulted in durable response rates in patients with high-risk biochemically recurrent prostate cancer ...

An oncology research nurse balances patient care with rigorous data collection, emphasizing communication and collaboration ...

Panelists discuss how the care team identifies and manages symptoms in chronic graft-versus-host disease patients, particularly those with advanced disease, emphasizing key symptoms to monitor, ...

Chlorhexidine dressings, along with proper patient education, are key in preventing central line-associated blood stream infections in patients with cancer.

A group of advanced practice providers discuss treatment options for a woman with newly diagnosed, transplant-ineligible ...

The FDA approved osimertinib for locally advanced, unresectable stage III EGFR-mutated non-small cell lung cancer. The FDA approved osimertinib (Tagrisso) for the treatment of adults with locally ...